243 related articles for article (PubMed ID: 35119629)
1. Early Therapeutic Interventions for Newly Diagnosed Glioblastoma: Rationale and Review of the Literature.
Waqar M; Trifiletti DM; McBain C; O'Connor J; Coope DJ; Akkari L; Quinones-Hinojosa A; Borst GR
Curr Oncol Rep; 2022 Mar; 24(3):311-324. PubMed ID: 35119629
[TBL] [Abstract][Full Text] [Related]
2. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Ashby LS; Smith KA; Stea B
World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma.
De Bonis P; Anile C; Pompucci A; Fiorentino A; Balducci M; Chiesa S; Maira G; Mangiola A
Acta Neurochir (Wien); 2012 Aug; 154(8):1371-8. PubMed ID: 22718138
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
[TBL] [Abstract][Full Text] [Related]
5. Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity.
Miglierini P; Bouchekoua M; Rousseau B; Hieu PD; Malhaire JP; Pradier O
Clin Neurol Neurosurg; 2012 Nov; 114(9):1222-5. PubMed ID: 22464950
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
Salmaggi A; Milanesi I; Silvani A; Gaviani P; Marchetti M; Fariselli L; Solero CL; Maccagnano C; Casali C; Guzzetti S; Pollo B; Ciusani E; Dimeco F
J Neurosurg; 2013 Apr; 118(4):821-9. PubMed ID: 23350777
[TBL] [Abstract][Full Text] [Related]
7. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
8. Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme.
Smith KA; Ashby LS; Gonzalez LF; Brachman DG; Thomas T; Coons SW; Battaglia M; Scheck A
J Neurosurg; 2008 Dec; 109 Suppl():106-17. PubMed ID: 19123896
[TBL] [Abstract][Full Text] [Related]
9. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.
Kleinberg LR; Weingart J; Burger P; Carson K; Grossman SA; Li K; Olivi A; Wharam MD; Brem H
Cancer Invest; 2004; 22(1):1-9. PubMed ID: 15069758
[TBL] [Abstract][Full Text] [Related]
10. Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel.
Salmaggi A; Duri S; Silvani A; Gaviani P; Milanesi I; Casali C; Di Meco F
Neurol Sci; 2011 Nov; 32 Suppl 2():S241-5. PubMed ID: 21983866
[TBL] [Abstract][Full Text] [Related]
11. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Noël G; Schott R; Froelich S; Gaub MP; Boyer P; Fischer-Lokou D; Dufour P; Kehrli P; Maitrot D
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):749-55. PubMed ID: 21300471
[TBL] [Abstract][Full Text] [Related]
12. Polymeric drug delivery for the treatment of glioblastoma.
Wait SD; Prabhu RS; Burri SH; Atkins TG; Asher AL
Neuro Oncol; 2015 Mar; 17 Suppl 2(Suppl 2):ii9-ii23. PubMed ID: 25746091
[TBL] [Abstract][Full Text] [Related]
13. Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit.
Sage W; Guilfoyle M; Luney C; Young A; Sinha R; Sgubin D; McAbee JH; Ma R; Jefferies S; Jena R; Harris F; Allinson K; Matys T; Qian W; Santarius T; Price S; Watts C
J Neurooncol; 2018 Jan; 136(2):273-280. PubMed ID: 29139095
[TBL] [Abstract][Full Text] [Related]
14. Brain tumor and Gliadel wafer treatment.
Panigrahi M; Das PK; Parikh PM
Indian J Cancer; 2011; 48(1):11-7. PubMed ID: 21330749
[TBL] [Abstract][Full Text] [Related]
15. Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Lin SH; Kleinberg LR
Expert Rev Anticancer Ther; 2008 Mar; 8(3):343-59. PubMed ID: 18366283
[TBL] [Abstract][Full Text] [Related]
16. [Results for Treatment of Newly-Diagnosed Glioblastoma Using Carmustine Wafers(Gliadel
Kumabe T; Shibahara I; Saito R
No Shinkei Geka; 2018 May; 46(5):367-376. PubMed ID: 29794312
[No Abstract] [Full Text] [Related]
17. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of carmustine wafers in the treatment of glioblastoma multiforme: a systematic review.
Zhang YD; Dai RY; Chen Z; Zhang YH; He XZ; Zhou J
Turk Neurosurg; 2014; 24(5):639-45. PubMed ID: 25269031
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.
Pallud J; Audureau E; Noel G; Corns R; Lechapt-Zalcman E; Duntze J; Pavlov V; Guyotat J; Hieu PD; Le Reste PJ; Faillot T; Litre CF; Desse N; Petit A; Emery E; Voirin J; Peltier J; Caire F; Vignes JR; Barat JL; Langlois O; Dezamis E; Parraga E; Zanello M; Nader E; Lefranc M; Bauchet L; Devaux B; Menei P; Metellus P;
Neuro Oncol; 2015 Dec; 17(12):1609-19. PubMed ID: 26185110
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
